FRAX Adjustments/FRAX 2

Session approved for 1 ASRT Category A Credit
Session approved for up to 1 AMA PRA Category 1 Credits™

This session duration is 50 minutes.

FRAX has been available since 2008 and is widely used worldwide. This lecture will provide a background to FRAX, its potential and limitations, and ongoing efforts to update the FRAX tool. These updates range from taking account of less-validated risk factors (adjustments) to a full redevelopment of the FRAX risk factor calculation engine.

Learning Objectives:

  • Identify basis of fracture probability compared to fracture risk
  • Explain the minimum requirements for inclusion of risk factors within FRAX
  • Describe the potential use of adjustments to FRAX probabilities

Eugene McCloskey, MD

University of Sheffield Metabolic Bone Centre

Eugene McCloskey is Professor in Adult Bone Diseases in the Academic Unit of Bone Metabolism and Mellanby Centre for Musculoskeletal Research at the University of Sheffield; and Director of the MRC Versus Arthritis Centre for Integrated Research in Musculoskeletal Ageing (www.CIMAuk.org). He has published over 430 peer-reviewed publications, book chapters and reviews and is an acknowledged authority in the fields of vertebral fracture definition, osteoporosis epidemiology and treatment, fracture risk assessment and bone health in cancer. He contributed to the development of the FRAX tool and the subsequent guideline from the National Osteoporosis Guideline Group. Professor McCloskey is on a number of editorial boards and is a member of committees within organisations including the boards of IOF and ESCEO. He is also the past President of the Bone Research Society. In 2016, he was awarded the IOF Medal of Achievement, presented annually to recognise an individual researcher who has significantly advanced the field of osteoporosis through original and outstanding scientific contributions. In 2018, he was honoured with the ECTS Philippe Bordier Award for a significant clinical contribution to the field of bone and calcified tissue.

Disclosures: 

Amgen (Self) : Advisory Board (Status: Ongoing), Consultant (Status: Ongoing), Research Support (Status: Ongoing); Fresenius Kabi (Self) : Advisory Board (Status: Terminated --- ), Consultant (Status: Terminated --- ); Obseva (Self) : Advisory Board (Status: Terminated --- ), Independent Contractor (Status: Terminated --- ); UCB (Self) : Advisory Board (Status: Ongoing), Independent Contractor (Status: Ongoing)

Kaitlyn Barrett, DO (Moderator)

Endocrinologist

The University of Vermont Medical Center

Kaitlyn Barrett, DO, is an Endocrinologist and Assistant Professor at the University of Vermont Medical Center and Larner College of Medicine where she also serves as the Associate Program Director of the Endocrine Fellowship Program. She completed her endocrine fellowship and internal medicine residency training at UVMMC, and recieved her medical degree from New York Institute of Technology College of Osteopathic Medicine in 2014. Clinical interests include osteoporosis and calcium disorders, diabetes and cardiometabolic disease.

Disclosures: No relationships to disclose.

Key:

Complete
Failed
Available
Locked
Recorded Archive
Select the "View On-Demand Recording" button to begin.
Select the "View On-Demand Recording" button to begin.
Session
03/31/2022 at 12:30 PM (EDT)   |  50 minutes
03/31/2022 at 12:30 PM (EDT)   |  50 minutes
Survey
10 Questions
Medical Certificate
Up to 1.00 medical credits available  |  No certificate available
Up to 1.00 medical credits available  |  No certificate available